Cargando…
Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations
Background: Nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs (NNRTIs) with boosted protease inhibitors are included in standardized first-line and second-line regimens. Recent World Health Organization (WHO) guidelines recommend a boosted protease inhibitor (PI) combined with 2 NRTI...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107847/ https://www.ncbi.nlm.nih.gov/pubmed/30174599 http://dx.doi.org/10.3389/fphar.2018.00890 |
_version_ | 1783350042343505920 |
---|---|
author | Huang, Yinqiu Huang, Xiaojie Luo, Yadong Zhou, Yihong Tao, Xingbao Chen, Hui Song, Aixin Chen, Yaokai Wu, Hao |
author_facet | Huang, Yinqiu Huang, Xiaojie Luo, Yadong Zhou, Yihong Tao, Xingbao Chen, Hui Song, Aixin Chen, Yaokai Wu, Hao |
author_sort | Huang, Yinqiu |
collection | PubMed |
description | Background: Nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs (NNRTIs) with boosted protease inhibitors are included in standardized first-line and second-line regimens. Recent World Health Organization (WHO) guidelines recommend a boosted protease inhibitor (PI) combined with 2 NRTIs or raltegravir as a second-line regimen. Objective: Ritonavir-boosted lopinavir (LPV/r) is known as a key second-line antiretroviral therapy (ART) in resource-limited settings. We carried out a meta-analysis to analyze virologic suppression and effectiveness of LPV/r-based second-line therapy in HIV-infected patients. Methods: In this meta-analysis, we searched randomized controlled trials and observational cohort studies to evaluate outcomes of second-line ART for patients with HIV who failed first-line therapy. A systematic search was conducted in Pubmed, Cochrane Library, and Embase from inception to January 2018. Outcomes included viral suppression, CD4 cell counts, drug resistance, adverse events, and self-reported adherence. We assessed comparative efficacy and safety in a meta-analysis. Data analysis was performed using RevMan 5.3 and Stata12.0. Results: Nine studies comprising 3,923 patients were included in the meta-analysis. The overall successful virologic suppression rate of the second-line regimen was 77% (ITT) and 87% (PP) at 48 weeks with a plasma HIV RNA load of <400 copies/mL. No statistical significance was found in CD4 cell count recoveries between LPV/r plus 2-3 NRTIs and simplified regimens (LPV/r plus raltegravir) at 48 weeks (P = 0.09), 96 weeks (P = 0.05), and 144 weeks (P = 0.73). Four studies indicated that the virus had low-level resistance to LPV/r, and the most common clinically significant PI-resistance mutations were 46I, 54V, 82A/82F, and 76V; however, no virologic failure due to LPV/r resistance was detected. In addition, no statistical significance was found between the two groups in self-reported adherence [relative risks (RR) = 1.03,95% confidence interval (CI) 1.00, 1.07, P = 0.06], grade 3 or 4 adverse events (RR = 0.84, 95% CI 0.64, 1.10, P = 0.20) or serious events (RR = 0.85, 95% CI 0.77, 1.17, P = 0.62). Conclusions: These results suggest that the LPV/r-based regimen demonstrates efficacious and low resistance as second-line antiretroviral therapy.Both LPV/r plus 2-3 NRTIs and LPV/r plus RAL regimens improved CD4 cell counts. There was no evidence of superiority of simplified regimens over LPV/r plus 2-3 NRTIs. |
format | Online Article Text |
id | pubmed-6107847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61078472018-08-31 Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations Huang, Yinqiu Huang, Xiaojie Luo, Yadong Zhou, Yihong Tao, Xingbao Chen, Hui Song, Aixin Chen, Yaokai Wu, Hao Front Pharmacol Pharmacology Background: Nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs (NNRTIs) with boosted protease inhibitors are included in standardized first-line and second-line regimens. Recent World Health Organization (WHO) guidelines recommend a boosted protease inhibitor (PI) combined with 2 NRTIs or raltegravir as a second-line regimen. Objective: Ritonavir-boosted lopinavir (LPV/r) is known as a key second-line antiretroviral therapy (ART) in resource-limited settings. We carried out a meta-analysis to analyze virologic suppression and effectiveness of LPV/r-based second-line therapy in HIV-infected patients. Methods: In this meta-analysis, we searched randomized controlled trials and observational cohort studies to evaluate outcomes of second-line ART for patients with HIV who failed first-line therapy. A systematic search was conducted in Pubmed, Cochrane Library, and Embase from inception to January 2018. Outcomes included viral suppression, CD4 cell counts, drug resistance, adverse events, and self-reported adherence. We assessed comparative efficacy and safety in a meta-analysis. Data analysis was performed using RevMan 5.3 and Stata12.0. Results: Nine studies comprising 3,923 patients were included in the meta-analysis. The overall successful virologic suppression rate of the second-line regimen was 77% (ITT) and 87% (PP) at 48 weeks with a plasma HIV RNA load of <400 copies/mL. No statistical significance was found in CD4 cell count recoveries between LPV/r plus 2-3 NRTIs and simplified regimens (LPV/r plus raltegravir) at 48 weeks (P = 0.09), 96 weeks (P = 0.05), and 144 weeks (P = 0.73). Four studies indicated that the virus had low-level resistance to LPV/r, and the most common clinically significant PI-resistance mutations were 46I, 54V, 82A/82F, and 76V; however, no virologic failure due to LPV/r resistance was detected. In addition, no statistical significance was found between the two groups in self-reported adherence [relative risks (RR) = 1.03,95% confidence interval (CI) 1.00, 1.07, P = 0.06], grade 3 or 4 adverse events (RR = 0.84, 95% CI 0.64, 1.10, P = 0.20) or serious events (RR = 0.85, 95% CI 0.77, 1.17, P = 0.62). Conclusions: These results suggest that the LPV/r-based regimen demonstrates efficacious and low resistance as second-line antiretroviral therapy.Both LPV/r plus 2-3 NRTIs and LPV/r plus RAL regimens improved CD4 cell counts. There was no evidence of superiority of simplified regimens over LPV/r plus 2-3 NRTIs. Frontiers Media S.A. 2018-08-14 /pmc/articles/PMC6107847/ /pubmed/30174599 http://dx.doi.org/10.3389/fphar.2018.00890 Text en Copyright © 2018 Huang, Huang, Luo, Zhou, Tao, Chen, Song, Chen and Wu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Huang, Yinqiu Huang, Xiaojie Luo, Yadong Zhou, Yihong Tao, Xingbao Chen, Hui Song, Aixin Chen, Yaokai Wu, Hao Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations |
title | Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations |
title_full | Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations |
title_fullStr | Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations |
title_full_unstemmed | Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations |
title_short | Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations |
title_sort | assessing the efficacy of lopinavir/ritonavir-based preferred and alternative second-line regimens in hiv-infected patients: a meta-analysis of key evidence to support who recommendations |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107847/ https://www.ncbi.nlm.nih.gov/pubmed/30174599 http://dx.doi.org/10.3389/fphar.2018.00890 |
work_keys_str_mv | AT huangyinqiu assessingtheefficacyoflopinavirritonavirbasedpreferredandalternativesecondlineregimensinhivinfectedpatientsametaanalysisofkeyevidencetosupportwhorecommendations AT huangxiaojie assessingtheefficacyoflopinavirritonavirbasedpreferredandalternativesecondlineregimensinhivinfectedpatientsametaanalysisofkeyevidencetosupportwhorecommendations AT luoyadong assessingtheefficacyoflopinavirritonavirbasedpreferredandalternativesecondlineregimensinhivinfectedpatientsametaanalysisofkeyevidencetosupportwhorecommendations AT zhouyihong assessingtheefficacyoflopinavirritonavirbasedpreferredandalternativesecondlineregimensinhivinfectedpatientsametaanalysisofkeyevidencetosupportwhorecommendations AT taoxingbao assessingtheefficacyoflopinavirritonavirbasedpreferredandalternativesecondlineregimensinhivinfectedpatientsametaanalysisofkeyevidencetosupportwhorecommendations AT chenhui assessingtheefficacyoflopinavirritonavirbasedpreferredandalternativesecondlineregimensinhivinfectedpatientsametaanalysisofkeyevidencetosupportwhorecommendations AT songaixin assessingtheefficacyoflopinavirritonavirbasedpreferredandalternativesecondlineregimensinhivinfectedpatientsametaanalysisofkeyevidencetosupportwhorecommendations AT chenyaokai assessingtheefficacyoflopinavirritonavirbasedpreferredandalternativesecondlineregimensinhivinfectedpatientsametaanalysisofkeyevidencetosupportwhorecommendations AT wuhao assessingtheefficacyoflopinavirritonavirbasedpreferredandalternativesecondlineregimensinhivinfectedpatientsametaanalysisofkeyevidencetosupportwhorecommendations |